Crinetics Pharmaceuticals (CRNX) Net Margin (2017 - 2026)
Crinetics Pharmaceuticals' (CRNX) quarterly Net Margin came in at 2322.28% in Q1 2026, down 2912948.0% year-on-year from N/an in Q1 2025, and down 16.67% quarter-over-quarter from 1990.5% in Q4 2025.
Crinetics Pharmaceuticals (CRNX) Net Margin (2017 - 2026) Analysis & Trends
Crinetics Pharmaceuticals' Net Margin history runs 10 years deep, the most recent figure standing at 2322.28% for Q1 2026.
- On a quarterly basis, Net Margin fell 2912948.0% year-over-year to 2322.28% in Q1 2026; TTM through Mar 2026 was 2138.26%, a 390221.0% decrease from a year earlier, with the FY2025 full-year figure at 6046.22%, up 2262924.0% from the prior year.
- Net Margin retreated to 2322.28% in Q1 2026 per CRNX's latest filing, from 1990.5% in the prior quarter.
- Across five years, Net Margin topped out at 26807.2% in Q1 2025 and bottomed at 90972.73% in Q3 2025.
- The 5-year median for Net Margin is 7749.81% (2022), against an average of 1507.36%.
- Across the five-year window, Net Margin soared 2345961 bps in 2022 and plunged 2912948 bps in 2026, its largest moves.
- Year by year, Net Margin stood at 6345.7% in 2022, then soared by 157 bps to 16318.21% in 2023, then grew by 14 bps to 18560.15% in 2024, then plunged by 111 bps to 1990.5% in 2025, then dropped by 17 bps to 2322.28% in 2026.
- Per Business Quant, the three latest CRNX Net Margin figures stand at 2322.28% (Q1 2026), 1990.5% (Q4 2025), and 90972.73% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Crinetics Pharmaceuticals | 8.71 Bn | 8.71 Bn | 10.53 Mn | -2,322.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,322.28% |
| Dec 31, 2025 | -1,990.50% |
| Sep 30, 2025 | -90,972.73% |
| Jun 30, 2025 | 11,216.00% |
| Mar 31, 2025 | 26,807.20% |
| Jun 30, 2024 | 18,560.15% |
| Mar 31, 2024 | 10,384.38% |
| Sep 30, 2023 | 16,318.21% |
| Jun 30, 2023 | 5,159.82% |
| Mar 31, 2023 | 1,716.87% |
| Dec 31, 2022 | 6,345.70% |
| Sep 30, 2022 | 9,153.93% |
| Jun 30, 2022 | 9,652.62% |
| Mar 31, 2022 | 1,073.68% |
| Dec 31, 2021 | -17,113.91% |
| Dec 31, 2020 | 31,039.44% |
| Mar 31, 2020 | -51,336.62% |
| Dec 31, 2019 | -4,628.97% |
| Sep 30, 2019 | -6,859.01% |
| Mar 31, 2019 | -13,129.70% |